DUBLIN–(BUSINESS WIRE)–The “US DoD Unmanned Aerial Vehicles Growth Opportunities” report has been added to ResearchAndMarkets.com’s…
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed…
The correction refers to the administrative costs for the period January – December 2021 that…
HONG KONG, Mar 25, 2022 – (ACN Newswire) – Kindstar Globalgene Technology, Inc. (“Kindstar Globalgene”…
NEW YORK, Mar 25, 2022 – (ACN Newswire) – Deloitte’s United States Economic Forecast Q1…
HONG KONG, Mar 25, 2022 – (ACN Newswire) – Analogue Holdings Limited (“Analogue” or the…
Companies Will Create New Opportunities in Such Areas as Licensing and Merchandising, Animation, Brand Partnerships,…
– CSI Shareholders Approved Merger Proposal at Special Meeting on March 25, 2022 – CSI…
Positioning Based on Customer Satisfaction, Customer Service Delivery, Growth, Innovation and Digital Banking Capabilities AUSTIN,…
LAS VEGAS–(BUSINESS WIRE)–The Siegel Group Nevada, Inc., a Commercial Real Estate & Development Company, announced…
International Conference on Alzheimer’s and Parkinson’s Diseases Provides New Insights into the Role of Neuroinflammation…
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex”), a majority-owned…
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people…
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response…
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of…
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single…
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) — Noema Pharma, a Swiss-based clinical-stage company targeting…
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life…
– Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than…
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase…